{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:26:39Z","timestamp":1773930399466,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA233878\\u201301"],"award-info":[{"award-number":["R01CA233878\\u201301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.acra.2025.11.025","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T20:32:20Z","timestamp":1764448340000},"page":"1005-1011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6430-6496","authenticated-orcid":false,"given":"Mohamad M.","family":"Alzein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha H.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2025.11.025_bib1","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per Milliliter","author":"Thompson","year":"2004","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.acra.2025.11.025_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.acra.2025.11.025_bib3","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.18632\/oncotarget.12554","article-title":"Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles","volume":"8","author":"Hoang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.acra.2025.11.025_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.acra.2025.11.025_bib5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.025_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.acra.2025.11.025_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncr.30336","article-title":"Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and\/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial","volume":"123","author":"Loriot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.acra.2025.11.025_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/pcan.2013.41","article-title":"et al.,Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acra.2025.11.025_bib9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","article-title":"Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort","volume":"121","author":"Rouyer","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.acra.2025.11.025_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.119.233429","article-title":"Additional local therapy for liver metastases in patients with metastatic castration-resistant prostate cancer receiving systemic PSMA-targeted therapy","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2025.11.025_bib11","first-page":"1932","article-title":"Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [177 Lu]Lu-PSMA-617","volume":"65","author":"Muniz","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2025.11.025_bib12","first-page":"734","article-title":"Prostate cancer liver metastasis: an ominous metastatic site in need of distinct management strategies","volume":"13","author":"Shiner","year":"2024","journal-title":"J\u00a0Clin\u00a0Med"},{"key":"10.1016\/j.acra.2025.11.025_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00432-013-1564-4","article-title":"A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases","volume":"140","author":"Saxena","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.acra.2025.11.025_bib14","first-page":"52","article-title":"Interventional liver-directed therapy for neuroendocrine metastases: current status and future directions","volume":"21","author":"D\u2019Souza","year":"2020","journal-title":"Curr\u00a0Treat\u00a0Options\u00a0Oncol"},{"key":"10.1016\/j.acra.2025.11.025_bib15","first-page":"1590","article-title":"Role of radioembolization in metastatic neuroendocrine tumors","volume":"45","author":"Lewandowski","year":"2022","journal-title":"Cardiovasc Interv\u00a0Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib16","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jvir.2014.07.007","article-title":"Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy","volume":"25","author":"Gordon","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","article-title":"Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma","volume":"33","author":"Kallini","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.acra.2025.11.025_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jvir.2022.05.023","article-title":"Yttrium-90 radioembolization for liver-dominant metastatic prostate cancer: a case series","volume":"33","author":"Bibok","year":"2022","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1159\/000478004","article-title":"Successful Yttrium-90 microsphere radioembolization for hepatic metastases of prostate cancer","volume":"10","author":"Bunck","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.acra.2025.11.025_bib20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00270-020-02612-4","article-title":"Intra-hepatic abscopal effect following radioembolization of hepatic metastases","volume":"43","author":"Powerski","year":"2020","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib21","first-page":"1591","article-title":"Outcomes analysis of Yttrium-90 radioembolization for tumors other than metastatic colorectal cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry","volume":"35","author":"Zhou","year":"2024","journal-title":"J\u00a0Vasc\u00a0Interv\u00a0Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib22","first-page":"1251","article-title":"Radioembolization with 90Yttrium microspheres: a State-of-the-Art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations","volume":"17","author":"Salem","year":"2006","journal-title":"J\u00a0Vasc\u00a0Interv\u00a0Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib23","first-page":"1425","article-title":"Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics","volume":"17","author":"Salem","year":"2006","journal-title":"J\u00a0Vasc\u00a0Interv\u00a0Radiol"},{"key":"10.1016\/j.acra.2025.11.025_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acra.2025.11.025_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00008-7","article-title":"AI model using clinical images for genomic prediction and tailored treatment in patients with cancer","volume":"26","author":"Guo","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acra.2025.11.025_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.acra.2025.11.025_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-025-02369-9","article-title":"Current AI technologies in cancer diagnostics and treatment","volume":"24","author":"Tiwari","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225010773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225010773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:31:49Z","timestamp":1773919909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633225010773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1076633225010773"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.11.025","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}